Investors

After years of scientific research, clinical development and collaboration with leading healthcare professionals, we are taking the next major step in our journey: bringing EUTEGRA to market.

From the development of MBK-01 to clinical validation and access through compassionate use programs in more than 40 hospitals, we have built the evidence and experience needed to advance microbiota-based therapy into clinical practice.

Today, EUTEGRA marks the transition from clinical development to market, providing a new therapeutic alternative for recurrent Clostridioides difficile infection.

This milestone opens a new chapter for Mikrobiomik as we continue to advance our platform and develop new therapeutic applications based on the intestinal microbiota.

Shareholders

Our current shareholders, in addition to the founding partners, include:

  • Orza, a direct investment entity, belonging to the Elkarkidetza and Geroa pension funds.
  • Seed Capital Bizkaia, a public company attached to the Department of Economic Promotion of the Provincial Council of Bizkaia, which is strongly committed to fostering innovation, social impact and the promotion and regeneration of the entrepreneurial network in Bizkaia.
  • San Ignacio S.L, a “family office” specially oriented to support disruptive projects.

News

AUGUST 2024

Successful crowdfunding campaign

In November 2025, we successfully closed our crowdfunding campaign in partnership with Capital Cell. Initially launched with a €500,000 target, the campaign exceeded expectations, surpassing €620,000 in investment.

This strong investor response reinforces confidence in Mikrobiomik’s strategy, technology and growth potential at a key stage in our journey towards the market launch of EUTEGRA.

MARCH 2025

Capital increase €1.6 M

We have confirmed a capital increase worth €1.6 million. This new milestone has been achieved thanks to the contribution of most of Mikrobiomik’s current partners.

Three new investors have joined this new round of financing, two of which are family offices from Spain and one is a business angel directly related to the global pharmaceutical industry.

MARCH 2024

Capital increase €1 M

A new capital increase for the amount of 1 million euros, has been completed. This new fund raising is another accomplishment that demonstrates the commitment of the current partners with the company and Mikrobiomik project.

One of the main uses of the funds will be to cover the costs associated with the regulatory strategy to bring MBK-01 to market.

SEPTEMBER 2023

Capital increase €1.1 M

We have confirmed a capital increase worth 1.1 million euros. This milestone is materialized thanks to the exclusive contribution of its current partners, who are determined to fulfill their initial mission: launch their investigational biological medicine, MBK-01, onto the European market.

Since its founding in 2018, Mikrobiomik has raised a significant sum of capital, demonstrating the trust and support of partners, such as Orza and Seed Capital Bizkaia. In addition, 11 other partners, including family offices and founding partners, have believed in the project since its inception.